Cairo – Mubasher: The Egyptian International Pharmaceutical Industries (EIPICO) reported consolidated net profits of EGP 358.69 million in the first nine months of 2021, up by 5.6% year-on-year (YoY) from EGP 339.46 million, including minority shareholders' rights.
The net sales increased to EGP 2.48 billion in the January-September period of 2021, compared to EGP 2.16 billion in the prior-year period, the company said in a bourse disclosure on Sunday.
As for standalone business, the company posted net profits of EGP 326.03 million in the nine-month period ended 30 September, up from EGP 281.51 million in the corresponding period a year earlier.
In the first half (H1) of 2021, EIPICO achieved consolidated net profits of EGP 270.76 million, slightly up from EGP 262.2 million in H1-20.
